Ali Behbahani
CIK 1613867 · last filed 2026-06-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.15B
Companies
25
Total Filings
136
Lifetime Open-Market Net
$216.94M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NKTX | Director | — | $2.86 | — | $0 | 7 | 2026-06-11 |
| KRRO | Director | 1,297,893 | $11.61 | $15.07M | $0 | 5 | 2026-06-11 |
| CRSP | Director | 270 | $49.80 | $13.4K | $0 | 11 | 2026-06-09 |
| Arcellx, Inc. (ACLX) Delisted | Director | 0 | $115.07 | $0 | $0 | 7 | 2026-04-28 |
| BDTX | Director | 4,542,325 | $1.75 | $7.95M | $20.20M | 27 | 2026-03-20 |
| SGP | Director | 2,989,408 | $18.44 | $55.12M | $15.00M | 2 | 2026-02-11 |
| NeueHealth, Inc. (BHG) Delisted | Director | 674,554 | $16.35 | $11.03M | $34.97M | 8 | 2025-10-06 |
| Adaptimmune Therapeutics PLC (ADAP) Delisted | Director | 14,671,794 | $0.06 | $849.5K | $4.77M | 8 | 2025-08-19 |
| GLUE | Director | 2,715,968 | $18.23 | $49.53M | $19.95M | 6 | 2025-06-16 |
| NeueHealth, Inc. (NEUE) Delisted | 10%+ Owner | — | $6.75 | — | $0 | 2 | 2024-10-03 |
| MBX | 10%+ Owner | 3,114,486 | $35.51 | $110.60M | $8.00M | 1 | 2024-09-17 |
| CVRX | Director | 316 | $5.03 | $1.6K | $0 | 6 | 2024-06-07 |
| SVRA | 10%+ Owner | 24,471,264 | $5.26 | $128.72M | $1000.0K | 1 | 2023-07-19 |
| MIRM | 10%+ Owner | 0 | $99.34 | $0 | $6.75M | 2 | 2023-06-15 |
| Oyster Point Pharma, Inc. (OYST) Delisted | Director | 3,573 | $11.17 | $39.9K | $0 | 4 | 2023-01-04 |
| Akouos, Inc. (AKUS) Delisted | 10%+ Owner | 0 | $13.29 | $0 | $10.00M | 2 | 2022-12-02 |
| UTRS | Director | 58,279 | $0.00 | $6 | $0 | 2 | 2022-06-14 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Director | 0 | $0.00 | $0 | $21.03M | 9 | 2022-05-26 |
| TRVI | 10%+ Owner | 10,421,428 | $14.21 | $148.09M | $31.80M | 4 | 2022-04-13 |
| Metacrine, Inc. (MTCR) Delisted | 10%+ Owner | 2,563,257 | $0.49 | $1.27M | $9.51M | 2 | 2021-12-27 |
| MRKR | 10%+ Owner | 10,714,285 | $1.38 | $14.79M | $10.00M | 1 | 2021-03-18 |
| Regulus Therapeutics Inc. (RGLS) Delisted | 10%+ Owner | 6,451,056 | $8.16 | $52.64M | $3.96M | 3 | 2020-12-07 |
| ASND | Director | 12,000,000 | $218.06 | $2.62B | $20.00M | 5 | 2019-07-03 |
| NEVRO CORP (NVRO) Delisted | Director | 5,390 | $5.84 | $31.5K | $0 | 8 | 2018-05-23 |
| CRISPR Therapeutics AG (PZRX) Delisted | Director | — | — | — | $0 | 2 | 2017-06-02 |
Recent Filings · Page 2 of 14
136 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-09-22 | BDTX | Grant (A) | +4,291 | $14.4K | EDGAR |
| 2025-08-19 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Sell (S) | −19,500,000 | -$229.2K | EDGAR |
| 2025-08-14 | Arcellx, Inc. (ACLX) Delisted | Other (J) | +4,207 | $0 | EDGAR |
| 2025-06-20 | BDTX | Grant (A) | +6,170 | $14.4K | EDGAR |
| 2025-06-16 | GLUE | Grant (A) | — | $0 | EDGAR |
| 2025-06-12 | KRRO | Grant (A) | — | $0 | EDGAR |
| 2025-06-12 | BDTX | Grant (A) | — | $0 | EDGAR |
| 2025-06-09 | NKTX | Grant (A) | — | $0 | EDGAR |
| 2025-06-06 | CRSP | Grant (A) | — | $0 | EDGAR |
| 2025-05-30 | Arcellx, Inc. (ACLX) Delisted | Grant (A) | — | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.